Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT ID: NCT07015190 Phase: PHASE3 Sponsor: IDEAYA Biosciences Status: Recruiting

SUMMARY

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

KEY ELIGIBILITY CRITERIA

- * Primary non-metastatic uveal melanoma
- * Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements
- * ECOG 0 or 1
- * Adequate organ function
- * Previous treatment for UM
- * Evidence of metastatic UM
- * Attributes that necessitate enucleation regardless of response to therapy
- * Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments
- * Presence of a malignant disease other than the one being treated in this study

ENROLLMENT CONTACT

Odette Houghton, MD Principal Investigator

Mayo Clinic Scottsdale - PPDS

Scottsdale, Arizona, United States

Total sites: 94 | 25 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT07015190) and public sources. Generated by FindMyCure.ai.